As mitochondrial activity and glycolysis are associated with disease progression in multiple myeloma [25], we assessed the impact on multiple myeloma cell metabolism of βAR‐blockers that target β1, β2, or both subtypes. This evidence concerns the gene ADRB2 and plasma cell myeloma.